ChemicalBook > CAS DataBase List > EXANTA

EXANTA

Product Name
EXANTA
CAS No.
192939-46-1
Chemical Name
EXANTA
Synonyms
EXANTA;Exarta;CS-1834;H 376/95;Exanta (TN);XIMELEGATRAN;EXANTA/XIMELEGATRAN;Exanta (XiMelagatran);Ximelagatran [USAN:INN];Ximelagatran (H 376/95)
CBNumber
CB7838374
Molecular Formula
C24H35N5O5
Formula Weight
473.57
MOL File
192939-46-1.mol
More
Less

EXANTA Property

Melting point:
65-68?C
Density 
1.35±0.1 g/cm3(Predicted)
storage temp. 
-20°C
solubility 
DMSO : 250 mg/mL (527.91 mM; Need ultrasonic)Methanol : 62.5 mg/mL (131.98 mM; Need ultrasonic)
pka
6.87±0.69(Predicted)
form 
powder
color 
white to beige
Stability:
Hygroscopic
InChIKey
PMOVWDINZOACJB-RBBKRZOGSA-N
SMILES
C(OCC)(=O)CN[C@H](C1CCCCC1)C(N1CC[C@H]1C(NCC1=CC=C(C=NNO)C=C1)=O)=O
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
SML1768
Product name
Ximelagatran
Purity
≥98% (HPLC)
Packaging
5MG
Price
$179
Updated
2025/07/31
Sigma-Aldrich
Product number
SML1768
Product name
Ximelagatran
Purity
≥98% (HPLC)
Packaging
25MG
Price
$718
Updated
2025/07/31
Cayman Chemical
Product number
16862
Product name
Ximelagatran
Purity
≥98%
Packaging
1mg
Price
$35
Updated
2024/03/01
Cayman Chemical
Product number
16862
Product name
Ximelagatran
Purity
≥98%
Packaging
10 mg
Price
$313
Updated
2024/03/01
Cayman Chemical
Product number
16862
Product name
Ximelagatran
Purity
≥98%
Packaging
500μg
Price
$71
Updated
2023/01/06
More
Less

EXANTA Chemical Properties,Usage,Production

Description

Ximelagatran, a prodrug of melagatran with improved oral bioavailability, is a direct thrombin inhibitor that was launched for the prevention of venous thromboembolic events (VTE) in elective hip or knee replacement surgery in Germany with several European countries following with approval for the same indication. A mutual recognition European filing was subsequently submitted for the prevention of stroke and other thromboembolic complications associated with atrial fibrillation (AF). While studies indicate that ximelagatran is as effective as traditional therapies for preventing strokes and recurring blood clots, the U.S. Food and Drug Administration has currently declined approval due to potential hepatotoxicity. Elevation of alanine aminotransferase (three times the upper limit of normal) has been observed in the first four months of therapy, but levels regress to normal upon discontinuation of the drug. Despite the questions surrounding the toxicological consequences of this elevated liver enzyme, ximelagatran remains an attractive alternative to the current antithrombotic therapies that utilize either the low molecular weight heparin (LMWH) or warfarin. Since LMWH is administered subcutaneously once or twice daily, the oral agent ximelagatran is preferable for patient compliance. In addition to the convenience of oral therapy, ximelagatran does not require the frequent laboratory monitoring and dosage adjustment that is necessary with warfarin treatment. A clinical study comparing the efficacy of a fixed dose (36 mg b.i.d.) of ximelagatran with adjusted dose warfarin for stroke prevention in patients with nonvalvular atrial fibrillation concluded that ximelagatran is not inferior to warfarin, and major bleeding occurred at rates similar to warfarin. The synthesis route to ximelagatran involves the coupling of the three major components, cyclohexylglycine, azetidine-2-carboxylic acid, and protected p-amidinobenzylamine, using solution-phase peptide chemistry. Subsequent alkylation of the N-terminus with ethyl bromoacetate, followed by deprotection of the amidine group and conversion to hydroxyamidine affords the double prodrug of melagatran. Delivery as ximelagatran provides reproducible oral bioavailability (18–25%), as measured by concentrations of the active metabolite melagatran formed by hydrolysis of the ethyl ester and dehydroxylation of the amidine. Melagatran reversibly binds to the arginine side pocket of both free and clot-bound thrombin (Ki=2 nM). Inhibition of thrombin ultimately blocks the conversion of fibrinogen to fibrin, the final step of the coagulation process. A linear relationship between ximelagatran dose and melagatran concentration exists with peak concentrations observed two to three hours post dose. Renal excretion is the primary route of elimination of melagatran (80%) with a half-life of 3–5 hours. Furthermore, the pharmacokinetics of ximelagatran is not influenced by the type of thromboembolic disease, obesity, ethnicity, gender, or age. In addition to the typical contraindications of current antithrombotic therapies, the increase in the liver enzyme alanine aminotransferase suggests that ximelagatran should not be used in patients with creatine clearance <30 mL/min. pending further study in this population. While ximelagatran does not appear to have any interactions with the cytochrome P-450 system, combination with aspirin has been shown to increase adverse bleeding.

Description

Ximelagatran is an ester prodrug of melagatran, a potent, direct, and reversible thrombin inhibitor (Ki = 1.2 nM). While melagatran has poor oral bioavailability, ximelagatran displays good bioavailability resulting, in part, from rapid absorption at the gastrointestinal tract, as well as rapid onset of action. Ximelagatran is converted to melagatran by reduction and hydrolysis at the liver and other tissues. It is used as an anticoagulant in a variety of situations, including thromboembolic disorders, stroke prevention in atrial fibrillation, and therapy in vein thrombosis.

Chemical Properties

Off-White Amorphous Solid

Originator

AstraZeneca (Germany)

Uses

An orally active direct thrombin inhibitor; prodrug of Melagatran. Antithrombotic.

Definition

ChEBI: A member of the class of azetidines that is melagatran in which the carboxylic acid group has been converted to the corresponding ethyl ester and in which the amidine group has been converted to the corresponding amidoxime. A prodrug for melagatran, ximela atran was the first orally available direct thrombin inhibitor to be brought to market as an anticoagulant, but was withdrawn in 2006 following reports of it causing liver damage.

brand name

Exanta (proposed) (AstraZeneca).

Biochem/physiol Actions

Ximelagatran is orally active, selective and potent direct thrombin inhibitor. Ximelagatran is a prodrug of thrombin inhibitor melagatran.

References

[1] BERND CLEMENT K L. Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug.[J]. Drug Metabolism and Disposition, 2003, 31 5: 645-651. DOI: 10.1124/dmd.31.5.645
[2] SHIR-JING HO  Tim A B. Ximelagatran: direct thrombin inhibitor.[J]. Vascular Health and Risk Management, 2006, 2 1: 49-58. DOI: 10.2147/vhrm.2006.2.1.49

EXANTA Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

EXANTA Suppliers

xinguokeji
Tel
13120711461
Email
363372932@qq.com
Country
China
ProdList
498
Advantage
58
Shanghai Boyle Chemical Co., Ltd.
Tel
Fax
86-21-57758967
Email
sales@boylechem.com
Country
China
ProdList
2922
Advantage
55
J & K SCIENTIFIC LTD.
Tel
18210857532; 18210857532
Fax
86-10-82849933
Email
jkinfo@jkchemical.com
Country
China
ProdList
96815
Advantage
76
Chemsky(shanghai)International Co.,Ltd.
Tel
021-50135380
Email
shchemsky@sina.com
Country
China
ProdList
32321
Advantage
50
Chizhou Kailong Import and Export Trade Co., Ltd.
Tel
Fax
-
Email
xg01_gj@163.com
Country
China
ProdList
9484
Advantage
50
Sigma-Aldrich
Tel
021-61415566 800-8193336
Email
orderCN@merckgroup.com
Country
China
ProdList
51395
Advantage
80
Shanghai Lollane Biological Technology Co.,Ltd.
Tel
021-52996696,15000506266 15000506266
Fax
+86-21-52996696
Country
China
ProdList
4768
Advantage
55
AN PharmaTech Co Ltd
Tel
86(21)68097365
Fax
86(21)33321566
Email
sales@anpharma.net
Country
China
ProdList
4891
Advantage
55
Pharmacodia (Beijing) Co.,Ltd
Tel
+86-400-851-9921
Fax
+86-10-82826195
Email
sales@pharmacodia.com
Country
China
ProdList
2317
Advantage
55
ShangHai Biochempartner Co.,Ltd
Tel
177-54423994 17754423994
Fax
QQ:2853530913
Email
2853530910@QQ.com
Country
China
ProdList
8000
Advantage
62
Shanghai Chaolan Chemical Technology Center
Tel
021-QQ:65489617 15618227136
Fax
21-5161 9052
Email
Sales@ATKchemical.com
Country
China
ProdList
9125
Advantage
58
Amadis Chemical Company Limited
Tel
571-89925085
Fax
0086-571-89925065
Email
sales@amadischem.com
Country
China
ProdList
131957
Advantage
58
Medi-tech Bioscientific Co., Ltd.
Tel
0519-83246372 13585352506
Fax
0519-83246372
Country
China
ProdList
1844
Advantage
58
Shanghai Biopharmaleader Co., Ltd.
Tel
+86 18721201413
Fax
+86 (21) 5775-8967
Email
sales@biopharmaleader.com
Country
China
ProdList
1720
Advantage
58
UHN Shanghai Research & Development Co., Ltd.
Tel
021-58958002 18930822973
Fax
021-58958618
Email
sales@uhnshanghai.com
Country
China
ProdList
1984
Advantage
58
Fujian boshi pharmaceutical technology co. LTD
Tel
0595-22008920; 18120708884
Email
393612455@qq.com
Country
China
ProdList
255
Advantage
58
Shenzhen Polymeri Biochemical Technology Co., Ltd.
Tel
+86-400-002-6226 +86-13028896684;
Email
sales@rrkchem.com
Country
China
ProdList
57422
Advantage
58
Changzhou Chenhong Biotechnology Co., Ltd.
Tel
+86-0519-85788828 +86-13775037613
Email
sales@chemrenpharm.com
Country
China
ProdList
3934
Advantage
58
Absin Bioscience Inc.
Tel
021-38015121 18438616290
Email
lanwu@univ-bio.com
Country
China
ProdList
24731
Advantage
58
Shanghai hongqu biomedical technology co. LTD
Tel
88888888888
Email
hongquchem@qq.com
Country
China
ProdList
5132
Advantage
58
Energy Chemical
Tel
021-58432009 400-005-6266
Fax
021-58436166
Email
marketing1@energy-chemical.com
Country
China
ProdList
44894
Advantage
58
Wuhan Topule
Tel
+86-02787215551 +86-19945035818
Fax
027-87215551
Email
2936752263@qq.com
Country
China
ProdList
7985
Advantage
58
Shanghai Sunway Pharmaceutical Technology Co.,Ltd.
Tel
021-51816796-820 13611835272
Fax
021-5161 3951
Email
sales2@sunwaypharm.com
Country
China
ProdList
44119
Advantage
58
Zhengzhou convergence chemical co., LTD
Tel
0371-0371-55153829 18003835034
Email
2853979819@qq.com
Country
China
ProdList
9998
Advantage
58
Beijing Jin Ming Biotechnology Co., Ltd.
Tel
010-60605840 15801484223;
Email
psaitong@jm-bio.com
Country
China
ProdList
29757
Advantage
58
Hubei Kele Fine Chemical Co., Ltd
Tel
027-59101668 19945030958
Fax
027-59101668
Email
2881924765@qq.com
Country
China
ProdList
7937
Advantage
58
Bide Pharmatech Ltd.
Tel
400-1647117 13681763483
Email
product02@bidepharm.com
Country
China
ProdList
59936
Advantage
58
Kaifeng Mingren Pharmaceutical Co.,LTD
Tel
0371-65741762
Fax
QQ:2860768577
Email
sales@hasunny.com
Country
China
ProdList
2380
Advantage
58
Wuhan Yingnuo Pharmaceutical Technology Co., Ltd.
Tel
15387063101
Email
2881924050@qq.com
Country
China
ProdList
9958
Advantage
58
TargetMol Chemicals Inc.
Tel
4008200310
Email
marketing@tsbiochem.com
Country
China
ProdList
24961
Advantage
58
Guangzhou Ruitai Chemical Co., Ltd.
Tel
18344585702
Email
550795326@qq.com
Country
China
ProdList
90
Advantage
58
Xianning Shen Lan Biomedical Research and Development Co., Ltd.
Tel
18171815831
Email
1341138380@qq.com
Country
China
ProdList
4309
Advantage
58
Wuhan Jingkangen Biomedical Technology Co., Ltd
Tel
13720134139 086-15871494362 13720134139
Email
orders@jknbiochem.com
Country
China
ProdList
6762
Advantage
58
https://hanhongsci.com/
Tel
021-54306202 18917919676
Email
info@hanhongsci.com
Country
China
ProdList
29995
Advantage
58
Nanjing Bic Biotechnology Co., Ltd
Tel
025-58906079 17352406906
Email
sales@bicbiotech.com
Country
China
ProdList
5996
Advantage
58
Nanjing Shizhou Biology Technology Co.,Ltd
Tel
025-85560043 15850508050
Fax
025-85563444
Email
cindy.huang@synzest.com
Country
China
ProdList
12000
Advantage
58
Shanghai jerryxing Biomedical Technology Co., Ltd
Tel
17721492509; 17721492509
Email
643638326@qq.com
Country
China
ProdList
4970
Advantage
58
Changsha Fuzhen Biotechnology Co.,LTD
Tel
0731-13823398 15111215862
Email
313359644@qq.com
Country
China
ProdList
4161
Advantage
58
RD International Technology Co., Limited
Tel
18024082417
Email
market@ubiochem.com
Country
China
ProdList
9835
Advantage
58
Jiangsu Aikon Biopharmaceutical R&D Co.,Ltd.
Tel
025-66061636 18013972705
Email
qqyang@aikonchem.com
Country
China
ProdList
10151
Advantage
58
Sangon Biotech (Shanghai) Co.,Ltd.
Tel
400-821-026
Email
Sales@sangon.com
Country
China
ProdList
6710
Advantage
58
Cayman Chemical Company
Tel
800-364-9897
Email
sales@caymanchem.com
Country
China
ProdList
6838
Advantage
58
Merck KGaA
Tel
21-20338288
Email
ordercn@merckgroup.com
Country
China
ProdList
6394
Advantage
58
Changzhou Xianglong Pharmaceutical Technology Co., Ltd.,
Tel
18915873328 18915873328
Email
296197970@qq.com
Country
China
ProdList
11051
Advantage
58
Biosynth Biological Technology (Suzhou) Co Ltd
Tel
51288865780
Email
sales@biosynth.com
Country
China
ProdList
6051
Advantage
58
Adooq Bioscience LLC
Tel
400-025-6535
Email
sales@adooq.cn
Country
China
ProdList
6215
Advantage
58
Santa Cruz Biotechnology Inc
Tel
021-60936350
Email
scbt@scbt.com
Country
China
ProdList
6594
Advantage
58
ATK CHEMICAL COMPANY LIMITED
Tel
+undefined-21-51877795
Fax
+86 21 5161 9052/ 5187 7796
Email
ivan@atkchemical.com
Country
China
ProdList
33024
Advantage
60
SHANGHAI KEAN TECHNOLOGY CO., LTD.
Tel
+8613817748580
Fax
021-50175322
Email
cooperation@kean-chem.com
Country
China
ProdList
40066
Advantage
58
Wuhan Jingkang en Biomedical Technology Co., Ltd
Tel
+8613720134139
Email
orders@jknbiochem.com
Country
China
ProdList
5221
Advantage
58

192939-46-1, EXANTARelated Search:


  • N-[(1R)-1-Cyclohexyl-2-[(2S)-2-[[[[4-[(hydroxyamino)iminomethyl]phenyl]methyl]amino]carbonyl]-1-azetidinyl]-2-oxoethyl]glycine Ethyl Ester
  • EXANTA
  • Glycine, N-[(1R)-1-cyclohexyl-2-[(2S)-2-[[[[4-[(hydroxyaMino)iMinoMethyl]phenyl]Methyl]aMino]carbonyl]-1-azetidinyl]-2-oxoethyl]-, ethyl ester
  • Exanta (XiMelagatran)
  • Ethyl 2-[[(1R)-1-Cyclohexyl-2-[(2S)-2-[[4-(N'-Hydroxycarbamimidoyl)Phenyl]Methylcarbamoyl]Azetidin-1-Yl]-2-Oxoethyl]Amino]Acetate Ximelagatran
  • Ethyl 2-[[(1R)-1-Cyclohexyl-2-[(2S)-2-[[4-(N'-Hydroxycarbamimidoyl)Phenyl]Methylcarbamoyl]Azetidin-1-Yl]-2-Oxoethyl]Amino]Acetate Ethyl 2-[[(1R)-1-Cyclohexyl-2-[(2S)-2-[[4-(N'-Hydroxycarbamimidoyl)Phenyl]Methylcarbamoyl]Azetidin-1-Yl]-2-Oxo-Ethyl
  • XIMELEGATRAN
  • EXANTA/XIMELEGATRAN
  • H 376/95
  • CS-1834
  • Exanta (TN)
  • EXANTA; EXARTA; H 376-95; EXANTA (TN); H 376/95; H 37695; XIMELAGATRAN [USAN:INN]; XIMELAGATRAN (JAN/USAN/INN)
  • Exarta
  • Ximelagatran (JAN/USAN/INN)
  • Ximelagatran [USAN:INN]
  • Ximelagatran (H 376/95)
  • Inhibitor,inhibit,Ximelagatran,Thrombin
  • Ethyl ((R)-1-cyclohexyl-2-((S)-2-((4-(N-hydroxycarbamimidoyl)benzyl)carbamoyl)azetidin-1-yl)-2-oxoethyl)glycinate
  • ethyl 2-{[(1R)-1-cyclohexyl-2-[(2S)-2-({[4-(N-hydroxycarbamimidoyl)phenyl]methyl}carbamoyl)azetidin-1-yl]-2-oxoethyl]amino}acetate
  • Ximelagatran, 10 mM in DMSO
  • 192939-46-1
  • C24H35N5O5
  • Aromatics
  • Chiral Reagents
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • Aromatics Compounds